Colon News and Research

RSS

Cancer genetics pioneer, Bert Vogelstein, awarded the Breakthrough Prize in Life Sciences

Bert Vogelstein, M.D., co-director of the Ludwig Center at Johns Hopkins and a Howard Hughes Medical Institute investigator has been awarded the Breakthrough Prize in Life Sciences. He was selected for his landmark work in cancer genomics and tumor suppressor genes.

21 Feb 2013

UCSD molecular biologist to receive Breakthrough Prize in Life Sciences

Napoleone Ferrara, MD, PhD, the molecular biologist credited with helping decipher how tumors grow and now senior deputy director for basic sciences at the University of California, San Diego Moores Cancer Center, was today named one of 11 recipients of the inaugural Breakthrough Prize in Life Sciences, which comes with a $3 million cash award.

21 Feb 2013

Four genetic variations may increase risk of colorectal cancer

An international research team co-led by cancer prevention researcher Ulrike "Riki" Peters, Ph.D., M.P.H., and biostatistician Hsu Li, Ph.D., at Fred Hutchinson Cancer Research Center has identified variations in four genes that are linked to an increased risk of colorectal cancer.

21 Feb 2013

‘Liver first’ approach first choice for metastatic rectal cancer

Using the “liver first” approach to treat locally advanced rectal cancer and synchronous liver metastases allows nearly three-quarters of patients to receive optimal neoadjuvant therapy and resection for both their primary tumor and metastases, researchers report.

20 Feb 2013

TIR-199 shows promise in fighting renal cancer

Chemists at the University of California, Riverside have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer.

20 Feb 2013

Researchers design molecules that can stop colon cancer progression

A Basque research consortium has managed to halt the progress of colon cancer and its metastasis in the liver in an experimental model with mice. This advance, that may open a new path for the future treatment of such pathologies, has been achieved by creating molecules which interfere with the adhesion of tumour cells to other cells of the organism. In this way, the molecules halt both the growth of the tumour and the dissemination of the tumour to and its proliferation in other organs.

19 Feb 2013

Colorectal cancer outcomes could be improved with regular genetic screening for Lynch syndrome

Cleveland Clinic researchers have found that colorectal cancer outcomes could be improved with regular genetic screening for Lynch syndrome, the most common hereditary, adult-onset cause of colorectal cancer, as published in the online version of the Journal of Clinical Oncology.

16 Feb 2013

Government of Québec announces $10M investment in Personalized Medicine Partnership for Cancer

The Government of Québec announced today a $10 million investment in the Personalized Medicine Partnership for Cancer (PMPC).

16 Feb 2013

Work stress ‘unlikely’ cause of cancer

Work-related stress is unlikely to be a major cause of cancer, say researchers who found no link between job strain and the risk for overall or site-specific malignancy.

11 Feb 2013

Study identifies 12 important postoperative complication signs in colorectal surgical patients

Colorectal surgical patients are often discharged from the hospital with vague guidance on how to recognize complications, but researchers at the Michael DeBakey Veterans Administration (VA) Medical Center and Baylor College of Medicine, Houston, aim to change that scenario.

11 Feb 2013

Scientists discover recurring pattern of more than 13,000 epigenetic alterations in young tumours

Tumourigenesis is driven by genetic alterations and by changes in the epigenome, for instance by the addition of methyl groups to cytosine bases in the DNA. A deeper understanding of the interaction between the genetic and epigenetic mechanisms is critical for the selection of tumour biomarkers and for the future development of therapies. Human tumour specimens and cell lines however contain a plethora of genetic and epigenetic changes, which complicate data analysis.

10 Feb 2013

New method can determine seriousness of cancer prognosis with 80% certainty

The number of incorrect cancer prognoses can be halved with computerised image analysis. In three years time, the method can be used on patients with bowel cancer, ovarian cancer and prostate cancer.

6 Feb 2013

Genomic Health fourth quarter total revenue increases to $60.4 million

Genomic Health, Inc. today reported financial results and business progress for the quarter and year ended December 31, 2012.

6 Feb 2013

Maimonides, Navidea to evaluate Lymphoseek use in lymphatic mapping for colorectal cancer

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it has entered into an agreement to collaborate with Maimonides Medical Center to investigate the utility of Lymphoseek (technetium Tc 99m tilmanocept) Injection in lymphatic mapping procedures for colorectal cancer.

5 Feb 2013

PKCζ protein plays a critical role in regulating tumor metabolism

Cancer cells need food to survive and grow. They're very good at getting it, too, even when nutrients are scarce. Many scientists have tried killing cancer cells by taking away their favorite food, a sugar called glucose. Unfortunately, this treatment approach not only fails to work, it backfires-glucose-starved tumors actually get more aggressive.

2 Feb 2013

Scientists uncover key mechanism that links obesity and diabetes with cancer

Sugars are needed to provide us with energy and in moderate amounts contribute to our well-being. Sustained high levels of sugars, as is found in diabetics, damages our cells and now is shown that can also increase our chance to get cancer: The dose makes the poison as Paracelsus said.

1 Feb 2013

Endothelial cells can trigger changes in cancer cells without direct contact

Blood vessels that supply oxygen and nutrients to tumors can also deliver something else - a signal that strengthens nearby cancer cells, making them more resistant to chemotherapy, more likely to spread to other organs and more lethal, scientists at The University of Texas MD Anderson Cancer Center report online in Cancer Cell.

1 Feb 2013

Teva terminates collaboration with CureTech

Teva Pharmaceutical Industries Ltd. announced today the termination of its collaboration with CureTech Ltd.

31 Jan 2013

UCSD molecular biologist to receive Charles Rodolphe Brupbacher Prize for Cancer Research

Molecular biologist Michael Karin is to receive this year's Charles Rodolphe Brupbacher Prize for Cancer Research in recognition of his studies on the role of chronic inflammation in the development of tumors. The award, which carries CHF 100,000 in prize money, is considered one of the highest accolades for cancer researchers worldwide. The awards ceremony takes place in Zurich this Thursday in the framework of an international symposium on "Breakthroughs in Cancer Research and Therapy".

30 Jan 2013

Colorectal cancer screening: an interview with Dr Donato F. Altomare

Colorectal cancer is a malignant neoplasm affecting the large bowel and the rectum mainly after the 5th decade of life and representing the second cause of death for cancer in western countries (the third in women). In about 15-20% of patients there is an inherited predisposition.

29 Jan 2013